Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,68.74,219,DB00641,Simvastatin
,31545497,inhibitor constant (Ki),"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,26.47,220,DB00641,Simvastatin
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,16.24,221,DB00641,Simvastatin
,31545497,Ki,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,10.84,222,DB00641,Simvastatin
,21632965,oral clearance,"The predicted oral clearance values of the drugs investigated ranged from 8.79 to 6320 l/h for tacrolimus and simvastatin, respectively, and were overall within 3-fold of the observed data with the exception of indinavir, atorvastatin, and buspirone.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[l] / [h],8.79 to 6320,1970,DB00641,Simvastatin
,21632965,CLu(int),"The individual HJM CLu(int) values ranged from 17 to 14,000 μl · min(-1) · mg(-1) for atorvastatin and saquinavir, respectively, and corresponding interindividual variability in CLu(int) estimates ranged from 41 to 67%.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[μl] / [mg·min],"17 to 14,000",1971,DB00641,Simvastatin
,21632965,F(G),"These in vitro data resulted in predicted F(G) values ranging from 0.03 to 0.94 for simvastatin and indinavir, respectively.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),,0,1972,DB00641,Simvastatin
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB00641,Simvastatin
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB00641,Simvastatin
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB00641,Simvastatin
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB00641,Simvastatin
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB00641,Simvastatin
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB00641,Simvastatin
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB00641,Simvastatin
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB00641,Simvastatin
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],9.6,9523,DB00641,Simvastatin
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],13.7,9524,DB00641,Simvastatin
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],34.3,9525,DB00641,Simvastatin
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],43.9,9526,DB00641,Simvastatin
,15811174,Serum concentration,"Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),[ng] / [l],8062.5,9832,DB00641,Simvastatin
,15811174,half-life,"The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),h,22.4,9833,DB00641,Simvastatin
,15811174,half-life,"The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),h,2.4,9834,DB00641,Simvastatin
<,26802130,tumor to plasma partition coefficient,"SVA exposure in tECF was <33.8 ± 11.9 µg/l per hour, whereas the tumor to plasma partition coefficient of SVA was <0.084 ± 0.008.",Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26802130/),,0.084,11170,DB00641,Simvastatin
,32918160,oral bioavailability,"However, due to its poor intrinsic water solubility, the drug is poorly absorbed from the gastrointestinal tract and exhibits a low oral bioavailability of approximately 5%.","A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32918160/),%,5,12006,DB00641,Simvastatin
,24556278,absolute bioavailability,The absolute bioavailability of calenduloside E was only 0.58%.,Pharmacokinetic study of calenduloside E and its active metabolite oleanolic acid in beagle dog using liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556278/),%,0.58,18841,DB00641,Simvastatin
,12942850,elimination half-life,"It is mainly eliminated in the faeces, with an elimination half-life in humans of between 13 and 21 hours.","[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942850/),h,13 and 21,26698,DB00641,Simvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB00641,Simvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB00641,Simvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB00641,Simvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB00641,Simvastatin
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],3.20,28337,DB00641,Simvastatin
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],6.78,28338,DB00641,Simvastatin
,11073847,area under the RLP-C curve,"Before treatment, FH patients had significantly higher fasting and postprandial concentrations of lipoprotein remnants (plasma RLP-C 42+/-19 mg/dL and area under the RLP-C curve 415+/-82 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),mg,415,34138,DB00641,Simvastatin
,11073847,RE,"Postprandial RE in the Sf<1000 fraction, not total RE in plasma, was also significantly higher in FH patients than in control subjects (24+/-10 versus 6.3+/-5.9 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),,24,34139,DB00641,Simvastatin
,11073847,RE,"Postprandial RE in the Sf<1000 fraction, not total RE in plasma, was also significantly higher in FH patients than in control subjects (24+/-10 versus 6.3+/-5.9 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),,6.3,34140,DB00641,Simvastatin
more,26572385,residence,The in vivo residence of thiomer placebo was more than 7h in rabbit.,Formulation of mucoadhesive gastric retentive drug delivery using thiolated xyloglucan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572385/),h,7,42157,DB00641,Simvastatin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,18.37,45135,DB00641,Simvastatin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,26.08,45136,DB00641,Simvastatin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,8.68,45137,DB00641,Simvastatin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,22.67,45138,DB00641,Simvastatin
>,9620098,trough:peak ratios,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),%,80,47827,DB00641,Simvastatin
,9620098,elimination half-life,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),h,17-25,47828,DB00641,Simvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB00641,Simvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB00641,Simvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB00641,Simvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB00641,Simvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB00641,Simvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB00641,Simvastatin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,1,52327,DB00641,Simvastatin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,2,52328,DB00641,Simvastatin
,32337660,terminal phase half-life,The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,11 to 18,52329,DB00641,Simvastatin
,32337660,absolute bioavailability,Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),%,100,52330,DB00641,Simvastatin
,28944193,half-life,"The retinal simvastatin concentration decayed exponentially, with a half-life of 1.92-2.41h.",The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28944193/),h,1.92-2.41,62310,DB00641,Simvastatin
,19277959,total run time,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),min,2.8,63151,DB00641,Simvastatin
,19277959,flow rate,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),[ml] / [min],0.50,63152,DB00641,Simvastatin
,22795942,flow rate,The mobile phase consisted of 0.02% ammonium acetate solution-methanol with a gradient program at a flow rate of 0.3 mL/min.,Simultaneous determination of imperatorin and its 2 metabolites in dog plasma by using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22795942/),[ml] / [min],0.3,63641,DB00641,Simvastatin
,32749629,mean dissolution time,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),min,10,65999,DB00641,Simvastatin
,32749629,dissolution rate,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),[μg] / [min],1253.,66000,DB00641,Simvastatin
,32749629,dissolution rate,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),[μg] / [min],166,66001,DB00641,Simvastatin
,32749629,relative bioavailability,"The obtained data reflected an improvement in the relative bioavailability of SMV with 148.232% which was confirmed by the significant reduction of the levels of circulating total cholesterol, triglycerides that reached the normal level after 12 h.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),%,148.232,66002,DB00641,Simvastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],2.1,69219,DB00641,Simvastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],1.0,69220,DB00641,Simvastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],0.4,69221,DB00641,Simvastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],12.1,69222,DB00641,Simvastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],4.5,69223,DB00641,Simvastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],1.9,69224,DB00641,Simvastatin
,29702479,Maximum plasma concentration (cmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),[μg] / [ml],21.86,71173,DB00641,Simvastatin
,29702479,Maximum plasma concentration (cmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),[μg] / [ml],8.25,71174,DB00641,Simvastatin
,29702479,time to reach it (tmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),h,1.4,71175,DB00641,Simvastatin
,29702479,time to reach it (tmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),h,3.0,71176,DB00641,Simvastatin
up to,29702479,Bioavailability,Bioavailability of the simvastatin complex relative to free drug was up to 167.0 %.,Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),%,167.0,71177,DB00641,Simvastatin
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB00641,Simvastatin
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB00641,Simvastatin
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB00641,Simvastatin
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB00641,Simvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB00641,Simvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB00641,Simvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB00641,Simvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB00641,Simvastatin
,17192506,area under the plasma concentration-time curve,"The mean (+/-SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 +/- 2.25 ng x h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 +/- 6.37 ng x h/mL; P = .013, Bonferroni test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[h·ng] / [ml],4.94,76394,DB00641,Simvastatin
,17192506,area under the plasma concentration-time curve,"The mean (+/-SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 +/- 2.25 ng x h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 +/- 6.37 ng x h/mL; P = .013, Bonferroni test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[h·ng] / [ml],16.35,76395,DB00641,Simvastatin
,17192506,oral clearance,"The mean (+/-SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 +/- 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 +/- 0.61 L/h; P < .05, Dunn's test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[l] / [h],4.80,76396,DB00641,Simvastatin
,17192506,oral clearance,"The mean (+/-SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 +/- 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 +/- 0.61 L/h; P < .05, Dunn's test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[l] / [h],1.35,76397,DB00641,Simvastatin
,27226460,flow rate,"The separation of all compounds was achieved in about 6.2 min using a C18 reverse-phase fused-core(®) column (Ascentis(®) Express C18) and a mobile phase, which was composed of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 3.8 with glacial acetic acid-acetonitrile (25:75, v/v), in isocratic mode at a flow rate of 0.500 mL/min.",Development and Validation of an LC-MS-MS Method for Determination of Simvastatin and Simvastatin Acid in Human Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226460/),[ml] / [min],0.500,78309,DB00641,Simvastatin
,27719741,terminal half-life,GSK2647544 was readily absorbed and its plasma concentration declined bi-exponentially with a terminal half-life ranging from 8 to 16 hours.,"Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers . ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27719741/),h,8 to 16,86740,DB00641,Simvastatin
,26345166,flow rate,"Following protein precipitation with acetonitrile, the NA, NUA, and internal standard (5-fluorouracil) were separated on a Zorbax 300SB-C8 column (250 mm × 4.6 mm, 5 μm) with a mobile phase consisting of methanol-2 mM ammonium acetate (3 : 97, v/v) at a flow rate of 1 mL/min (split 1 : 1).",Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26345166/),[ml] / [min],1,86982,DB00641,Simvastatin
<,19636709,total release of,Release of simvastatin from the cubic nanoparticles was limited both in 0.1 M hydrochloride solution containing 0.2% sodium lauryl sulfate and fasted-state simulated intestinal fluid with a total release of <3.0% at 10 h.,Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19636709/),%,3.0,87319,DB00641,Simvastatin
,19636709,relative oral bioavailability,The relative oral bioavailability of simvastatin cubic nanoparticles calculated on the basis of area under the curve was 241% compared to simvastatin crystal powder.,Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19636709/),%,241,87320,DB00641,Simvastatin
,18205133,flow-rate,"Chromatographic separation was carried out on an Acquity UPLC BEH C(18) column with mobile phase consisting of acetonitrile-water (containing 5 mmol/L ammonium acetate; 85:15, v/v) at a flow-rate of 0.35 mL/min.",Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205133/),[ml] / [min],0.35,90125,DB00641,Simvastatin
shorter,18205133,analysis time,The analysis time was shorter than 1.7 min per sample.,Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205133/),-1·min,1.7,90126,DB00641,Simvastatin
>,29403775,Recovery,Recovery was >58% for SIM and >75% for SIMA in both plasma and cell lysate.,Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403775/),%,58,90173,DB00641,Simvastatin
>,29403775,Recovery,Recovery was >58% for SIM and >75% for SIMA in both plasma and cell lysate.,Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403775/),%,75,90174,DB00641,Simvastatin
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB00641,Simvastatin
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB00641,Simvastatin
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB00641,Simvastatin
,18254152,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 179 --> 137, 137 --> 93 and 435 --> 319 for ASA, SA and IS, respectively.","Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254152/),,179,92858,DB00641,Simvastatin
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,1·91,94193,DB00641,Simvastatin
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,3·81,94194,DB00641,Simvastatin
,16671968,absorption rate,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),1/[h],1,95456,DB00641,Simvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,14,95457,DB00641,Simvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2,95458,DB00641,Simvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2.5,95459,DB00641,Simvastatin
,16671968,input rate (K(in)),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),[g] / [d·l],0.14,95460,DB00641,Simvastatin
,16671968,inhibition fraction of K(in),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),,0.21,95461,DB00641,Simvastatin
,16671968,dose,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95462,DB00641,Simvastatin
,16671968,L,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95463,DB00641,Simvastatin
,22358108,50% inhibition concentration (IC(50)),Simvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 3.0 μM.,"Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),μM,3.0,95725,DB00641,Simvastatin
,22358108,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) values of diltiazem in the presence of simvastatin (1.0 mg/kg) were significantly (p < 0.05) higher (44.8%) than that of the control group.","Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),%,44.8,95726,DB00641,Simvastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,97,99614,DB00641,Simvastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,98,99615,DB00641,Simvastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,109,99616,DB00641,Simvastatin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00641,Simvastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00641,Simvastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00641,Simvastatin
,23692066,peak plasma SMV concentration,The peak plasma SMV concentration increased from 2.3 μg/mL with pure SMV to 3.8 μg/mL with dendrimer formulations.,Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692066/),[μg] / [ml],2.3,104591,DB00641,Simvastatin
,23692066,peak plasma SMV concentration,The peak plasma SMV concentration increased from 2.3 μg/mL with pure SMV to 3.8 μg/mL with dendrimer formulations.,Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692066/),[μg] / [ml],3.8,104592,DB00641,Simvastatin
,16542205,half-life,"The half-life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild-type SLCO1B1*1a/*1a genotype (12.2 +/- 1.6 h vs. 14.5 +/- 1.4 h, P = 0.01).","Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542205/),h,12.2,107239,DB00641,Simvastatin
,16542205,half-life,"The half-life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild-type SLCO1B1*1a/*1a genotype (12.2 +/- 1.6 h vs. 14.5 +/- 1.4 h, P = 0.01).","Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542205/),h,14.5,107240,DB00641,Simvastatin
,26903278,time,Adjunctive treatment with 60 mg/kg simvastatin shortened the time required to achieve culture-negative lungs from 4.5 to 3.5 months.,Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),month,4.5,108363,DB00641,Simvastatin
,26903278,time,Adjunctive treatment with 60 mg/kg simvastatin shortened the time required to achieve culture-negative lungs from 4.5 to 3.5 months.,Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),month,3.5,108364,DB00641,Simvastatin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,100,108365,DB00641,Simvastatin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,50,108366,DB00641,Simvastatin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,0,108367,DB00641,Simvastatin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,20,108368,DB00641,Simvastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],25,108570,DB00641,Simvastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],14,108571,DB00641,Simvastatin
,26519618,total run time,Polarity switch (positive-negative-positive ionization mode) was performed in a total run time of 4.0min.,"Validated UPLC-MS/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519618/),min,4.0,113414,DB00641,Simvastatin
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,5.9,113992,DB00641,Simvastatin
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,3.7,113993,DB00641,Simvastatin
,27048644,run time,"A volume of plasma sample of only 400 µL was processed by the solid phase extraction technique; then 20 µL of processed sample was run on a Phenomenex, Kinetix XB C18, 150 × 4.6 mm, 5 µm column using an isocratic mobile phase consisting of 10 mM ammonium formate buffer (pH 4.0 ± 0.3): acetonitrile (27 : 73, v/v) with a run time of 6.3 min.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),min,6.3,114026,DB00641,Simvastatin
,27048644,Cmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,10.61,114027,DB00641,Simvastatin
,27048644,Cmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,69.74,114028,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,77.58,114029,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,69.74,114030,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,190.71,114031,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,1.74,114032,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,25.36,114033,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,139.24,114034,DB00641,Simvastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,3.95,114035,DB00641,Simvastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,1.74,114036,DB00641,Simvastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,25.36,114037,DB00641,Simvastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,139.24,114038,DB00641,Simvastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,3.95,114039,DB00641,Simvastatin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,11.28,120465,DB00641,Simvastatin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,8.90,120466,DB00641,Simvastatin
,19127869,T(1/2),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,8.01,120467,DB00641,Simvastatin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],103.41,120468,DB00641,Simvastatin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],190.23,120469,DB00641,Simvastatin
,19127869,AUC(0-infinity),"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[h·ng] / [ml],421.66,120470,DB00641,Simvastatin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,6.31,120471,DB00641,Simvastatin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,5.98,120472,DB00641,Simvastatin
,19127869,MRT,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),h,6.18,120473,DB00641,Simvastatin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],30.10,120474,DB00641,Simvastatin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],29.58,120475,DB00641,Simvastatin
,19127869,CL/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),[l] / [h·kg],31.18,120476,DB00641,Simvastatin
,19127869,Vd/F,"The main pharmacokinetic parameters of retinamido-ester after oral administration via gastric gavage of 2.5, 5, 10 mg x kg(-1) were as follows, T(1/2): (11.28 +/- 7.23), (8.90 +/- 3.82), (8.01 +/- 5.65) h; AUC(0-infinity): (103.41 +/- 61.46), (190.23 +/- 74.99), (421.66 +/- 229.20) ng x h x mL(-1); MRT: (6.31 +/- 0.75), (5.98 +/- 0.71), (6.18 +/- 0.97) h; CL/F: (30.10 +/- 13.67), (29.58 +/- 10.59), (31.18 +/- 17.51) L x h(-1) x kg(-1); Vd/F: (414.94 +/- 159.82), (356.16 +/- 139.85), (369.28 +/- 322.72) L x kg(-1), respectively.",Quantitative determination and pharmacokinetics of retinamido-ester in rat plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19127869/),,414.94,120477,DB00641,Simvastatin
,29403892,positive at retention time,MS/MS detection involved a switch of electron spray ionization mode from negative to positive at retention time 3.01 min.,Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),min,3.01,124908,DB00641,Simvastatin
,29403892,m/,"The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d4, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d6.",Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),,408.3,124909,DB00641,Simvastatin
,29403892,m/,"The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d4, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d6.",Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),,419.30,124910,DB00641,Simvastatin
,29403892,m/,"The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d4, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d6.",Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),,28,124911,DB00641,Simvastatin
,29403892,m/z,"The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d4, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d6.",Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),,425.40,124912,DB00641,Simvastatin
,29403892,m/z,"The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d4, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d6.",Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403892/),,199.20,124913,DB00641,Simvastatin
over,30167890,EE%,"With the weight ratio of TPGS-to-PLGA in organic phase of 30% and TPGS-to-lipid in aqueous phase of 35%, ST-TLPN exhibited core-shell structure, sub-100 nm size, EE% of over 90% and a slow release profile.",Fabrication of TPGS-Stabilized Liposome-PLGA Hybrid Nanoparticle Via a New Modified Nanoprecipitation Approach: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30167890/),%,90,124919,DB00641,Simvastatin
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00641,Simvastatin
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00641,Simvastatin
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00641,Simvastatin
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00641,Simvastatin
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00641,Simvastatin
,21128704,relative bioavailability,"The relative bioavailability of simvastatin from optimized SLNs was found to be 220%, substantiating the protective action of SLNs against liver metabolism.",Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128704/),%,220,129701,DB00641,Simvastatin
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB00641,Simvastatin
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00641,Simvastatin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00641,Simvastatin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00641,Simvastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,7.3,136145,DB00641,Simvastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,9.3,136146,DB00641,Simvastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,5.2,136147,DB00641,Simvastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136808,DB00641,Simvastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136809,DB00641,Simvastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136810,DB00641,Simvastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136811,DB00641,Simvastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136812,DB00641,Simvastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136813,DB00641,Simvastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],312,136814,DB00641,Simvastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136815,DB00641,Simvastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],3536,136816,DB00641,Simvastatin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,9.4,136817,DB00641,Simvastatin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,12.4,136818,DB00641,Simvastatin
,23469684,Tmax,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,1.44,137307,DB00641,Simvastatin
,23469684,Cmax,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),[μg] / [l],9.83,137308,DB00641,Simvastatin
,23469684,t1/2,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,4.85,137309,DB00641,Simvastatin
,23469684,AUC(0-infinity),"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),[h·μg] / [l],40.32,137310,DB00641,Simvastatin
,23469684,t1/2,"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137311,DB00641,Simvastatin
,23469684,Cmax,"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137312,DB00641,Simvastatin
,23469684,AUC(0-infinity),"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137313,DB00641,Simvastatin
,23469684,AUC(0-infinity),"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,4.41,137314,DB00641,Simvastatin
,29716858,maximum plasma concentration Cmax,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[ng] / [ml],2.47,140860,DB00641,Simvastatin
,29716858,maximum plasma concentration Cmax,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[ng] / [ml],5.66,140861,DB00641,Simvastatin
,29716858,area under time versus concentration curve from 0 to 10 hours AUC0-10,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[h·ng] / [ml],15.10,140862,DB00641,Simvastatin
,29716858,area under time versus concentration curve from 0 to 10 hours AUC0-10,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[h·ng] / [ml],58.49,140863,DB00641,Simvastatin
,19764585,recovery rates,"The established method was able to determine lovastatin in human plasma over the range of 0.03125-64 microg/L, with recovery rates ranging from 96% to 102%.",[Determination of lovastatin and its active metabolites in human plasma with high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764585/),%,96,142223,DB00641,Simvastatin
,19764585,recovery rates,"The established method was able to determine lovastatin in human plasma over the range of 0.03125-64 microg/L, with recovery rates ranging from 96% to 102%.",[Determination of lovastatin and its active metabolites in human plasma with high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764585/),%,102,142224,DB00641,Simvastatin
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4586,148575,DB00641,Simvastatin
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4928,148576,DB00641,Simvastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],30.5,148577,DB00641,Simvastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],20.0,148578,DB00641,Simvastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],43.0,148579,DB00641,Simvastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],23.4,148580,DB00641,Simvastatin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,441.1,150047,DB00641,Simvastatin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,325.2,150048,DB00641,Simvastatin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,408.2,150049,DB00641,Simvastatin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,235.1,150050,DB00641,Simvastatin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,278.1,150051,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,27,151996,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,80,151997,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),[μM] / [l],16,151998,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,75,151999,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,19.3,152000,DB00641,Simvastatin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,21.5,152001,DB00641,Simvastatin
,25138349,solubilizing capacity,Tween-80 also showed good solubilizing capacity which was 117 mg/ml.,"Preparation and evaluation of SEDDS of simvastatin by in vivo, in vitro and ex vivo technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138349/),[mg] / [ml],117,152763,DB00641,Simvastatin
,22229827,T(max),"Additionally, the T(max) of simvastatin nanocrystal group was 1.99 h, comparing to 2.88 h of reference group.",Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22229827/),h,1.99,159889,DB00641,Simvastatin
,22229827,T(max),"Additionally, the T(max) of simvastatin nanocrystal group was 1.99 h, comparing to 2.88 h of reference group.",Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22229827/),h,2.88,159890,DB00641,Simvastatin
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,41.8,166072,DB00641,Simvastatin
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,68.7,166073,DB00641,Simvastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],7.8,167666,DB00641,Simvastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],15.4,167667,DB00641,Simvastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],21.7,167668,DB00641,Simvastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],43.3,167669,DB00641,Simvastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],74.2,167670,DB00641,Simvastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],58.6,167671,DB00641,Simvastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],365,167672,DB00641,Simvastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],287,167673,DB00641,Simvastatin
,23971207,Cmax,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),[ng] / [ml],0.49,168487,DB00641,Simvastatin
,23971207,t(max),"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,1.6,168488,DB00641,Simvastatin
,23971207,AUC(0-infinity),"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),[h·ng] / [ml],1.08,168489,DB00641,Simvastatin
,23971207,t1/2kel,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,2.14,168490,DB00641,Simvastatin
,23971207,MRT,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,3.08,168491,DB00641,Simvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],48.0,169350,DB00641,Simvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],14.1,169351,DB00641,Simvastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],3.10,169352,DB00641,Simvastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,39.31,176348,DB00641,Simvastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,50,176349,DB00641,Simvastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,15.77,176350,DB00641,Simvastatin
,11259986,Cmax,"The mean Cmax and AUC(0,24 h) of simvastatin (95% confidence interval) when given alone were 8.76 (6.72-11.41) ng ml(-1) and 60.36 (47.15-77.28) ng ml(-1) h.",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),[ng] / [ml],8.76,177867,DB00641,Simvastatin
,11259986,"AUC(0,24 h)","The mean Cmax and AUC(0,24 h) of simvastatin (95% confidence interval) when given alone were 8.76 (6.72-11.41) ng ml(-1) and 60.36 (47.15-77.28) ng ml(-1) h.",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),[h·ng] / [ml],60.36,177868,DB00641,Simvastatin
,11259986,time to peak concentration (tmax,"No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,1.0,177869,DB00641,Simvastatin
,11259986,time to peak concentration (tmax,"No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,1.5,177870,DB00641,Simvastatin
,11259986,"half-life (t1/2,z","No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,8.5,177871,DB00641,Simvastatin
,25323804,t max,"Moreover, the median t max of simvastatin acid occurred earlier (1.8 h) when combined compared to 3.0 h when administered alone.","Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323804/),h,1.8,180659,DB00641,Simvastatin
,25323804,t max,"Moreover, the median t max of simvastatin acid occurred earlier (1.8 h) when combined compared to 3.0 h when administered alone.","Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323804/),h,3.0,180660,DB00641,Simvastatin
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],74.55,181395,DB00641,Simvastatin
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],67.55,181396,DB00641,Simvastatin
,10934672,time to peak serum concentration,The time to peak serum concentration for both treatments was 3 hours.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),h,3,181397,DB00641,Simvastatin
,29766530,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),[l] / [h],2.05,183022,DB00641,Simvastatin
,29766530,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),l,309,183023,DB00641,Simvastatin
,23631382,PS,The optimised NE showed PS of 132 ± 9 nm and zeta potential of 17.1 ± 1.2 mV.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),nm,132,183028,DB00641,Simvastatin
,23631382,zeta potential,The optimised NE showed PS of 132 ± 9 nm and zeta potential of 17.1 ± 1.2 mV.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),mv,17.1,183029,DB00641,Simvastatin
,23631382,relative bioavailability,Pharmacokinetic studies showed relative bioavailability of simvastatin NE was 369.0% with respect to PD suspension.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),%,369.0,183030,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,16.0,183649,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,43.5,183650,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,15.2,183651,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,28.4,183652,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,5.2,183653,DB00641,Simvastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,6.3,183654,DB00641,Simvastatin
,25387217,elimination half-life,The elimination half-life of albiglutide is approximately 5 days.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),d,5,188501,DB00641,Simvastatin
,25387217,Clearance,Clearance of albiglutide is 67 mL/h with between-subject variability of 34.9%; no covariates have been identified that would require dose adjustment of albiglutide.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),[ml] / [h],67,188502,DB00641,Simvastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],151,190014,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],75,190015,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],17,190016,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],548,190017,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],167,190018,DB00641,Simvastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],289,190019,DB00641,Simvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],24 319,190020,DB00641,Simvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],26 760,190021,DB00641,Simvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],15 565,190022,DB00641,Simvastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],14 571,190023,DB00641,Simvastatin
,18196524,total chromatographic run time,The total chromatographic run time was 3.0 min.,Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196524/),min,3.0,190848,DB00641,Simvastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],22.2,192219,DB00641,Simvastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],21.3,192220,DB00641,Simvastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],61.3,192221,DB00641,Simvastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],57.6,192222,DB00641,Simvastatin
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,25.2,192223,DB00641,Simvastatin
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,24.1,192224,DB00641,Simvastatin
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.6,192225,DB00641,Simvastatin
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.1,192226,DB00641,Simvastatin
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB00641,Simvastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB00641,Simvastatin
,23109219,maximum plasma drug concentration (C(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],81.56,200393,DB00641,Simvastatin
,23109219,maximum plasma drug concentration (C(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],9.40,200394,DB00641,Simvastatin
,23109219,time to reach C(max) (t(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,0.93,200395,DB00641,Simvastatin
,23109219,time to reach C(max) (t(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,1.25,200396,DB00641,Simvastatin
,23109219,elimination half-life (t(½)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,24.32,200397,DB00641,Simvastatin
,23109219,elimination half-life (t(½)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,18.90,200398,DB00641,Simvastatin
,23109219,area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],579.06,200399,DB00641,Simvastatin
,23109219,area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],126.01,200400,DB00641,Simvastatin
,23109219,C(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],11.92,200401,DB00641,Simvastatin
,23109219,C(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],3.37,200402,DB00641,Simvastatin
,23109219,t(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,0.98,200403,DB00641,Simvastatin
,23109219,t(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,3.73,200404,DB00641,Simvastatin
,23109219,t(½),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,4.19,200405,DB00641,Simvastatin
,23109219,t(½),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,7.65,200406,DB00641,Simvastatin
,23109219,AUC(last),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],33.63,200407,DB00641,Simvastatin
,23109219,AUC(last),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],32.50,200408,DB00641,Simvastatin
,19188036,flow rate,"The chromatographic separation was achieved using an isocratic mobile phase consisting of a mixture of acetonitrile and 0.5% formic acid (90:10 (v/v), pH 3.5) flowing through C18 column at a flow rate of 0.2ml/min.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),[ml] / [min],0.2,203269,DB00641,Simvastatin
,19188036,m,"Ions were monitored in positive mode and the mass transitions measured were m/z 268.1-->m/z 103.2, m/z 441.3-->m/z 325.1 and m/z 260.0-->m/z 129.5 for MET, SIM and WIS, respectively.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),,268.1,203270,DB00641,Simvastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,66.71,204073,DB00641,Simvastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,87.44,204074,DB00641,Simvastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,92.11,204075,DB00641,Simvastatin
,22544712,flow rate,"The reconstituted samples were chromatographed on an Alltima HP C(18) column using an isocratic solvent mixture [acetonitrile-5 mm ammonium acetate (pH 4.5), 85:15 (v/v)] at a flow rate of 1.0 mL/min.",Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),[ml] / [min],1.0,207551,DB00641,Simvastatin
,22544712,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),min,3.0,207552,DB00641,Simvastatin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208386,DB00641,Simvastatin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.9,208387,DB00641,Simvastatin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 091,208388,DB00641,Simvastatin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 323,208389,DB00641,Simvastatin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 123.88,208390,DB00641,Simvastatin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 385.98,208391,DB00641,Simvastatin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,4.7,208392,DB00641,Simvastatin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208393,DB00641,Simvastatin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 057,208394,DB00641,Simvastatin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 087,208395,DB00641,Simvastatin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 012.49,208396,DB00641,Simvastatin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 040.45,208397,DB00641,Simvastatin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,1.8,208398,DB00641,Simvastatin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,2.5,208399,DB00641,Simvastatin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],3.15,208400,DB00641,Simvastatin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.87,208401,DB00641,Simvastatin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],9.03,208402,DB00641,Simvastatin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],17.63,208403,DB00641,Simvastatin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,5.8,208404,DB00641,Simvastatin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,6.5,208405,DB00641,Simvastatin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.22,208406,DB00641,Simvastatin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],9.30,208407,DB00641,Simvastatin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],34.65,208408,DB00641,Simvastatin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],61.62,208409,DB00641,Simvastatin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,40.55,208410,DB00641,Simvastatin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,62.87,208411,DB00641,Simvastatin
,24162379,Peak plasma concentrations,"Peak plasma concentrations ranged from 0.08 to 2.2 and from 0.03 to 0.6 μM for simvastatin lactone and carboxylate, respectively.",Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24162379/),μM,0.08 to 2.2,208771,DB00641,Simvastatin
,24162379,Peak plasma concentrations,"Peak plasma concentrations ranged from 0.08 to 2.2 and from 0.03 to 0.6 μM for simvastatin lactone and carboxylate, respectively.",Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24162379/),μM,0.03 to 0.6,208772,DB00641,Simvastatin
,23180162,relative bioavailability,"In vivo, the relative bioavailability of SIM from super-SEDDDS increased significantly to 180 ± 53.3% (p = 0.014) compared to the dosing of two capsules of (dose equivalent) 75% drug-loaded SNEDDS.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),%,180,209588,DB00641,Simvastatin
,23180162,terminal half-life of elimination,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),h,2.3,209589,DB00641,Simvastatin
,23180162,terminal half-life of elimination,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),h,1.4,209590,DB00641,Simvastatin
,23180162,area under the curve ratio,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),,0.57,209591,DB00641,Simvastatin
,23180162,area under the curve ratio,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),,0.90,209592,DB00641,Simvastatin
,1904355,oral absorption,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,34,210347,DB00641,Simvastatin
,1904355,bioavailability,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,17,210348,DB00641,Simvastatin
,1904355,plasma elimination half-life,Peak blood level after oral administration is reached at approximately 1 h and the mean plasma elimination half-life is 1.8 h.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),h,1.8,210349,DB00641,Simvastatin
,1904355,Binding,Binding of total radioactivity to plasma proteins averages 45%.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,45,210350,DB00641,Simvastatin
,18724669,flow rate,"Simvastatin and the internal standard (lovastatin) were extracted from human plasma with diethyl ether-n-hexane-isopropanol (80: 20 : 3, v/v/v), then separated on a Waters ACQUITY UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 microm) with isocratic elution at a flow rate of 0.25 mL/min.",[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),[ml] / [min],0.25,211995,DB00641,Simvastatin
,18724669,m/z,2 --> m/z 199.0 and m/z 405.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,199.0,211996,DB00641,Simvastatin
,18724669,m/z,2 --> m/z 199.0 and m/z 405.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,405,211997,DB00641,Simvastatin
,18724669,0 --> m/z,"0 --> m/z 199.0 was used to quantify simvastatin and the internal standard, respectively.",[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,199.0,211998,DB00641,Simvastatin
,18724669,extraction recovery,The mean extraction recovery of simvastatin was 91.6%.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),%,91.6,211999,DB00641,Simvastatin
,27200472,flow rate,"The analytes were analyzed on an Acquity UPLC BEH C18 column, and a gradient program was applied at a flow rate of 0.2mL/min.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),[ml] / [min],0.2,212506,DB00641,Simvastatin
,27200472,extraction recoveries,"The average extraction recoveries were 90.1% and 91.9% for LOV and LOVA, and the matrix effects were found to be between 85% and 115%.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),%,90.1,212507,DB00641,Simvastatin
,27200472,extraction recoveries,"The average extraction recoveries were 90.1% and 91.9% for LOV and LOVA, and the matrix effects were found to be between 85% and 115%.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),%,91.9,212508,DB00641,Simvastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.050,215035,DB00641,Simvastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.134,215036,DB00641,Simvastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.255,215037,DB00641,Simvastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.277,215038,DB00641,Simvastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.105,215039,DB00641,Simvastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.248,215040,DB00641,Simvastatin
,30632800,polydispersity index,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),,0.32,216759,DB00641,Simvastatin
,30632800,zeta potential,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),mv,-12.5,216760,DB00641,Simvastatin
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,38.5,216761,DB00641,Simvastatin
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,72.2,216762,DB00641,Simvastatin
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],1.68,220946,DB00641,Simvastatin
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.62,220947,DB00641,Simvastatin
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,10.33,220948,DB00641,Simvastatin
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220949,DB00641,Simvastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220950,DB00641,Simvastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,11.41,220951,DB00641,Simvastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.16,220952,DB00641,Simvastatin
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.40,220953,DB00641,Simvastatin
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],5.16,220954,DB00641,Simvastatin
,20171425,T(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,8.40,220955,DB00641,Simvastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.57,220956,DB00641,Simvastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,13.09,220957,DB00641,Simvastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.52,220958,DB00641,Simvastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],8.75,222399,DB00641,Simvastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],5.77,222400,DB00641,Simvastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],3.93,222401,DB00641,Simvastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],2.45,222402,DB00641,Simvastatin
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00641,Simvastatin
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00641,Simvastatin
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00641,Simvastatin
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00641,Simvastatin
,34214011,AUC(0-t),Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [h·l],2018.58,225449,DB00641,Simvastatin
,34214011,AUC(0-t),Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [h·l],653.05,225450,DB00641,Simvastatin
,34214011,Cmax,Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [l],173.69,225451,DB00641,Simvastatin
,34214011,Cmax,Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [l],85.63,225452,DB00641,Simvastatin
,34214011,IC50,"Baicalein showed an inhibitory effect on the activity of CYP3A4 with the IC50 value of 12.03 μM, which is responsible for the metabolism of simvastatin.",Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),μM,12.03,225453,DB00641,Simvastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,80,226815,DB00641,Simvastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,18,226816,DB00641,Simvastatin
>,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,95,226817,DB00641,Simvastatin
,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,60,226818,DB00641,Simvastatin
,33393940,Half maximal inhibitory concentration,"Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) µg/mL and 15.24 (0.58) µg/mL, respectively, but they were higher than respective positive controls.","Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33393940/),[μg] / [ml],11.96,228319,DB00641,Simvastatin
,33393940,Half maximal inhibitory concentration,"Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) µg/mL and 15.24 (0.58) µg/mL, respectively, but they were higher than respective positive controls.","Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33393940/),[μg] / [ml],15.24,228320,DB00641,Simvastatin
,23698259,IC₅₀,"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],12.5,230414,DB00641,Simvastatin
,23698259,K(i)(app),"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],18.8,230415,DB00641,Simvastatin
,21915888,flow rate,"Separation of SV, LV, NIA and the IS was achieved on an Alltima C₁₈ column with a mobile phase consisting of 5 mm ammonium acetate (pH 4.5) and acetonitrile (20:80, v/v) pumped at a flow rate of 1 mL/min.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),[ml] / [min],1,233942,DB00641,Simvastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,2.12,233943,DB00641,Simvastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,1.67,233944,DB00641,Simvastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.50,233945,DB00641,Simvastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.65,233946,DB00641,Simvastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB00641,Simvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB00641,Simvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB00641,Simvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB00641,Simvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB00641,Simvastatin
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238835,DB00641,Simvastatin
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238836,DB00641,Simvastatin
,16028010,CL10,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238837,DB00641,Simvastatin
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238838,DB00641,Simvastatin
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238839,DB00641,Simvastatin
,16028010,CL12,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],4.8,238840,DB00641,Simvastatin
,16028010,CL21,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.6,238841,DB00641,Simvastatin
,16028010,CL,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238842,DB00641,Simvastatin
,16028010,CL12,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238843,DB00641,Simvastatin
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238844,DB00641,Simvastatin
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238845,DB00641,Simvastatin
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238846,DB00641,Simvastatin
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238847,DB00641,Simvastatin
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238848,DB00641,Simvastatin
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),,0.00,238849,DB00641,Simvastatin
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],2.3,238850,DB00641,Simvastatin
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],0.3,238851,DB00641,Simvastatin
>,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,200,238852,DB00641,Simvastatin
,16028010,IC5),"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,100,238853,DB00641,Simvastatin
,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,18,238854,DB00641,Simvastatin
,32446169,oral bioavailability,"The cholesterol-lowering agent, simvastatin (SIM), is poorly water-soluble and undergoes extensive first pass metabolism, resulting in a low oral bioavailability of approximately 5%.",Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32446169/),%,5,238967,DB00641,Simvastatin
,21730017,half-life,The typical estimated half-life of SB-649868 was 3-6 h - comparable with currently used hypnotic agents.,"Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730017/),h,3-6,242738,DB00641,Simvastatin
,33368422,Ka,A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),1/[h],1.83,247130,DB00641,Simvastatin
,33368422,clearance [CL/F],A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),[l] / [h],292,247131,DB00641,Simvastatin
,33368422,volume of distribution in the central compartment [Vc /F],A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),l,1506,247132,DB00641,Simvastatin
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,646,248572,DB00641,Simvastatin
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,698,248573,DB00641,Simvastatin
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.12,248574,DB00641,Simvastatin
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.13,248575,DB00641,Simvastatin
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.3,248576,DB00641,Simvastatin
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.6,248577,DB00641,Simvastatin
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,12,248578,DB00641,Simvastatin
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,23,248579,DB00641,Simvastatin
,19398603,area,"Furthermore, the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0 to 10 hours showed no significant differences among 3 statins (simvastatin: 0.32 +/- 0.09, atorvastatin: 0.31 +/- 0.09, and pitavastatin: 0.31 +/- 0.12).",Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398603/),,0,249583,DB00641,Simvastatin
,22612290,"half-life (t(1/2,eff) )","After ESL oral administration, the effective half-life (t(1/2,eff) ) of eslicarbazepine was 20-24 h, which is approximately two times longer than its terminal half-life (t(1/2)).",Pharmacokinetics and drug interactions of eslicarbazepine acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612290/),h,20-24,249977,DB00641,Simvastatin
,26888941,IC50,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,295,255854,DB00641,Simvastatin
,26888941,KI,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,216,255855,DB00641,Simvastatin
,26888941,kinact,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),1/[min],0.0179,255856,DB00641,Simvastatin
,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,157,255857,DB00641,Simvastatin
>,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,500,255858,DB00641,Simvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,1.59,255859,DB00641,Simvastatin
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.47,255860,DB00641,Simvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.26,255861,DB00641,Simvastatin
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,4.38,255862,DB00641,Simvastatin
,33494472,zeta potential,"The SIM-loaded niosomes showed EE% between 66.7-91.4%, vesicle size between 191.1-521.6 nm, and zeta potential ranged between -0.81-+35.6 mv.",Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33494472/),mv,35.6,256172,DB00641,Simvastatin
,33494472,cumulative percentage of drug released,The cumulative percentage of drug released was ranged from 55% to 94% over 12 h.,Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33494472/),%,55,256173,DB00641,Simvastatin
,33494472,cumulative percentage of drug released,The cumulative percentage of drug released was ranged from 55% to 94% over 12 h.,Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33494472/),%,94,256174,DB00641,Simvastatin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00641,Simvastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00641,Simvastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00641,Simvastatin
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,2.10,263398,DB00641,Simvastatin
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,15.52,263399,DB00641,Simvastatin
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,92.85-101.53,263400,DB00641,Simvastatin
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,94.51-117.75,263401,DB00641,Simvastatin
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,12,263402,DB00641,Simvastatin
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6,263403,DB00641,Simvastatin
,34079222,tlag,"AML-B was absorbed without any lag time (tlag) while tlag was 6.33 ± 0.81 h for SIM, thus met the study objective.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6.33,263404,DB00641,Simvastatin
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],349,265958,DB00641,Simvastatin
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],242,265959,DB00641,Simvastatin
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],24.5,265960,DB00641,Simvastatin
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],28.9,265961,DB00641,Simvastatin
,32405982,solubility,"SEM and XRD analysis conform; proliposomes are spherical, amorphous in nature, so that it enhances the solubility of SV between 15.01 ± 0.026 and 57.80 ± 0.015 μg/mL in pH 7.4 phosphate buffer.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],15.01,266919,DB00641,Simvastatin
,32405982,solubility,"SEM and XRD analysis conform; proliposomes are spherical, amorphous in nature, so that it enhances the solubility of SV between 15.01 ± 0.026 and 57.80 ± 0.015 μg/mL in pH 7.4 phosphate buffer.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],57.80,266920,DB00641,Simvastatin
,32405982,Tmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),h,2,266921,DB00641,Simvastatin
,32405982,Tmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),h,4,266922,DB00641,Simvastatin
,32405982,Cmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],10.4,266923,DB00641,Simvastatin
,32405982,Cmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],21.18,266924,DB00641,Simvastatin
,32405982,AUC0-∞,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [h·ml],67.124,266925,DB00641,Simvastatin
,32405982,AUC0-∞,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [h·ml],179.75,266926,DB00641,Simvastatin
,14612892,half-life,There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean reduction of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.,"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14612892/),h,1.4-2.7,268235,DB00641,Simvastatin
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.07,268540,DB00641,Simvastatin
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.92,268541,DB00641,Simvastatin
< or =,18855612,F(G),"An area of high intestinal extraction (F(G) < or = 0.25) is identified as problematic, as availability of conclusive data is limited in this area.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.25,268542,DB00641,Simvastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00641,Simvastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00641,Simvastatin
